Tim Weaver1, Nicola Metrebian2, Jennifer Hellier3, Stephen Pilling4, Vikki Charles2, Nicholas Little4, Dilkushi Poovendran1, Luke Mitcheson5, Frank Ryan6, Owen Bowden-Jones7, John Dunn6, Anthony Glasper8, Emily Finch5, John Strang9. 1. Centre for Mental Health, Imperial College London, London, UK. 2. King's College London National Addiction Centre, King's College London Institute of Psychiatry, King's College London, London, UK. 3. King's Clinical Trials Unit, Department of Biostatistics, King's College London Institute of Psychiatry, King's College London, London, UK. 4. Research Department of Clinical Educational and Health Psychology, University College London, London, UK. 5. South London & Maudsley NHS Foundation Trust, London, UK. 6. Camden and Islington NHS Foundation Trust, London, UK. 7. Central & North West London NHS Foundation Trust, London, UK. 8. Sussex NHS Foundation Trust, Worthing, UK. 9. King's College London National Addiction Centre, King's College London Institute of Psychiatry, King's College London, London, UK; South London & Maudsley NHS Foundation Trust, London, UK. Electronic address: john.strang@kcl.ac.uk.
Abstract
BACKGROUND: Poor adherence to treatment diminishes its individual and public health benefit. Financial incentives, provided on the condition of treatment attendance, could address this problem. Injecting drug users are a high-risk group for hepatitis B virus (HBV) infection and transmission, but adherence to vaccination programmes is poor. We aimed to assess whether contingency management delivered in routine clinical practice increased the completion of HBV vaccination in individuals receiving opioid substitution therapy. METHODS: In our cluster randomised controlled trial, we enrolled participants at 12 National Health Service drug treatment services in the UK that provided opioid substitution therapy and nurse-led HBV vaccination with a super-accelerated schedule (vaccination days 0, 7, and 21). Clusters were randomly allocated 1:1:1 to provide vaccination without incentive (treatment as usual), with fixed value contingency management (three £10 vouchers), or escalating value contingency management (£5, £10, and £15 vouchers). Both contingency management schedules rewarded on-time attendance at appointments. The primary outcome was completion of clinically appropriate HBV vaccination within 28 days. We also did sensitivity analyses that examined vaccination completion with full adherence to appointment times and within a 3 month window. The trial is registered with Current Controlled Trials, number ISRCTN72794493. FINDINGS:Between March 16, 2011, and April 26, 2012, we enrolled 210 eligible participants. Compared with six (9%) of 67 participants treated as usual, 35 (45%) of 78 participants in the fixed value contingency management group met the primary outcome measure (odds ratio 12·1, 95% CI 3·7-39·9; p<0·0001), as did 32 (49%) of 65 participants in the escalating value contingency management group (14·0, 4·2-46·2; p<0·0001). These differences remained significant with sensitivity analyses. INTERPRETATION: Modest financial incentives delivered in routine clinical practice significantly improve adherence to, and completion of, HBV vaccination programmes in patients receiving opioid substitution therapy. Achievement of this improvement in routine clinical practice should now prompt actual implementation. Drug treatment providers should employ contingency management to promote adherence to vaccination programmes. The effectiveness of routine use of contingency management to achieve long-term behaviour change remains unknown. FUNDING: National Institute for Health Research (RP-PG-0707-10149).
RCT Entities:
BACKGROUND: Poor adherence to treatment diminishes its individual and public health benefit. Financial incentives, provided on the condition of treatment attendance, could address this problem. Injecting drug users are a high-risk group for hepatitis B virus (HBV) infection and transmission, but adherence to vaccination programmes is poor. We aimed to assess whether contingency management delivered in routine clinical practice increased the completion of HBV vaccination in individuals receiving opioid substitution therapy. METHODS: In our cluster randomised controlled trial, we enrolled participants at 12 National Health Service drug treatment services in the UK that provided opioid substitution therapy and nurse-led HBV vaccination with a super-accelerated schedule (vaccination days 0, 7, and 21). Clusters were randomly allocated 1:1:1 to provide vaccination without incentive (treatment as usual), with fixed value contingency management (three £10 vouchers), or escalating value contingency management (£5, £10, and £15 vouchers). Both contingency management schedules rewarded on-time attendance at appointments. The primary outcome was completion of clinically appropriate HBV vaccination within 28 days. We also did sensitivity analyses that examined vaccination completion with full adherence to appointment times and within a 3 month window. The trial is registered with Current Controlled Trials, number ISRCTN72794493. FINDINGS: Between March 16, 2011, and April 26, 2012, we enrolled 210 eligible participants. Compared with six (9%) of 67 participants treated as usual, 35 (45%) of 78 participants in the fixed value contingency management group met the primary outcome measure (odds ratio 12·1, 95% CI 3·7-39·9; p<0·0001), as did 32 (49%) of 65 participants in the escalating value contingency management group (14·0, 4·2-46·2; p<0·0001). These differences remained significant with sensitivity analyses. INTERPRETATION: Modest financial incentives delivered in routine clinical practice significantly improve adherence to, and completion of, HBV vaccination programmes in patients receiving opioid substitution therapy. Achievement of this improvement in routine clinical practice should now prompt actual implementation. Drug treatment providers should employ contingency management to promote adherence to vaccination programmes. The effectiveness of routine use of contingency management to achieve long-term behaviour change remains unknown. FUNDING: National Institute for Health Research (RP-PG-0707-10149).
Authors: Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil Journal: J Subst Abuse Treat Date: 2016-06-24
Authors: Diann E Gaalema; Rebecca J Elliott; Patrick D Savage; Jason L Rengo; Alex Y Cutler; Irene Pericot-Valverde; Jeffrey S Priest; Donald S Shepard; Stephen T Higgins; Philip A Ades Journal: JACC Heart Fail Date: 2019-05-08 Impact factor: 12.035
Authors: David C Perlman; Ashly E Jordan; Courtney McKnight; Christopher Young; Kevin L Delucchi; James L Sorensen; Don C Des Jarlais; Carmen L Masson Journal: J Addict Dis Date: 2014
Authors: André Q C Miguel; Clarice S Madruga; Hugo Cogo-Moreira; Rodolfo Yamauchi; Viviane Simões; Claudio J da Silva; Sterling McPherson; John M Roll; Ronaldo R Laranjeira Journal: Psychol Addict Behav Date: 2016-07-21
Authors: Shannon Gwin Mitchell; Laura B Monico; Maxine Stitzer; Timothy Matheson; James L Sorensen; Daniel J Feaster; Robert P Schwartz; Lisa Metsch Journal: J Subst Abuse Treat Date: 2018-07-22